These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 4143952)
1. Contributions of neurochemistry to neurology and psychiatry. Introduction. Roberts E Fed Proc; 1973 Feb; 32(2):181-2. PubMed ID: 4143952 [No Abstract] [Full Text] [Related]
2. [Senile Parkinsonism: its motor and psychological defects]. Birkmayer W Aktuelle Gerontol; 1982 Sep; 12(5):166-7. PubMed ID: 6128932 [TBL] [Abstract][Full Text] [Related]
3. [Dynamics of slow potential changes in human subcortical structures during mental activity under conditions of directed changes in the brain internal medium]. Chernysheva VA Fiziol Zh SSSR Im I M Sechenova; 1971 Feb; 57(2):150-8. PubMed ID: 5579573 [No Abstract] [Full Text] [Related]
4. Neurotransmitters and their receptors in the basal ganglia. McGeer PL; McGeer EG Adv Neurol; 1993; 60():93-101. PubMed ID: 8093584 [No Abstract] [Full Text] [Related]
5. [Role of the basal ganglia in voluntary movement--a new concept]. Kimura M No To Shinkei; 1993 Jul; 45(7):605-16. PubMed ID: 8104446 [No Abstract] [Full Text] [Related]
6. Schizophrenia as a dynamical disease. an der Heiden U Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S36-42. PubMed ID: 16508894 [TBL] [Abstract][Full Text] [Related]
8. [Neurotransmitters, drugs and neuropsychiatric diseases (author's transl)]. Relja M; Lackvoić Z Lijec Vjesn; 1979 Oct; 101(10):609-16. PubMed ID: 44538 [No Abstract] [Full Text] [Related]
9. On the neuronal circuitries and neurotransmitters involved in the control of locomotor activity. Carlsson A J Neural Transm Suppl; 1993; 40():1-12. PubMed ID: 7905022 [TBL] [Abstract][Full Text] [Related]
10. [Physiopathology and symptomatology of parkinsonian movement disorders in the light of recent therapeutic progress]. Ferrari E Sist Nerv; 1970; 22(2):164-74. PubMed ID: 4926919 [No Abstract] [Full Text] [Related]
12. [Neurobiology of parkinsonism. I. Neural substrates an neurochemistry of the basal ganglia]. Ponzoni S; Garcia-Cairasco N Arq Neuropsiquiatr; 1995 Sep; 53(3-B):706-10. PubMed ID: 8585835 [TBL] [Abstract][Full Text] [Related]
13. Thirty years of dopamine research. Carlsson A Adv Neurol; 1993; 60():1-10. PubMed ID: 8093570 [No Abstract] [Full Text] [Related]
14. Convulsive seizures and electroencephalogram changes in three patients during levodopa therapy. McPherson A Neurology; 1970 Dec; 20(12):41-5. PubMed ID: 5531293 [No Abstract] [Full Text] [Related]
15. Electroencephalographic changes occurring during L-dopa treatment. Herman MN; Rowan AJ; Goldensohn ES Trans Am Neurol Assoc; 1971; 96():252-4. PubMed ID: 5159096 [No Abstract] [Full Text] [Related]
16. EEG and urinary non-catecholic amine changes during L-dopa therapy of Parkinson's disease. Marjerrison G; Boulton AA; Rajput AH Dis Nerv Syst; 1972 Mar; 33(3):164-9. PubMed ID: 5022451 [No Abstract] [Full Text] [Related]
17. Potential nondopaminergic drugs for Parkinson's disease. Silverdale MA; Fox SH; Crossman AR; Brotchie JM Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686 [No Abstract] [Full Text] [Related]
18. [New data on the physiopathology and current treatment of Parkinsonism. Introduction]. Pestel M Ann Med Interne (Paris); 1972 Apr; 123(4):337-40. PubMed ID: 5077037 [No Abstract] [Full Text] [Related]
19. Meditations on the future of clinical neurology. Folkerts JF Psychiatr Neurol Neurochir; 1973; 76(1):9-16. PubMed ID: 4699107 [No Abstract] [Full Text] [Related]
20. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Strange PG Mov Disord; 1993 Jul; 8(3):263-70. PubMed ID: 8101967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]